Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Accumulated Expenses (2016 - 2026)

Spero Therapeutics filings provide 10 years of Other Accumulated Expenses readings, the most recent being $133000.0 for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 10.83% to $133000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $133000.0, a 10.83% increase, with the full-year FY2025 number at $133000.0, up 10.83% from a year prior.
  • Other Accumulated Expenses hit $133000.0 in Q4 2025 for Spero Therapeutics, up from $82000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2021 to a low of $82000.0 in Q3 2025.
  • Median Other Accumulated Expenses over the past 5 years was $204000.0 (2021), compared with a mean of $391250.0.
  • Biggest five-year swings in Other Accumulated Expenses: surged 468.25% in 2023 and later plummeted 84.15% in 2024.
  • Spero Therapeutics' Other Accumulated Expenses stood at $1.2 million in 2021, then crashed by 83.17% to $209000.0 in 2022, then rose by 12.92% to $236000.0 in 2023, then plummeted by 49.15% to $120000.0 in 2024, then increased by 10.83% to $133000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $133000.0 (Q4 2025), $82000.0 (Q3 2025), and $89000.0 (Q2 2025) per Business Quant data.